|
T63013 |
Ruboxistaurin
|
|
|
|
Ruboxistaurin (LY333531) is a selective, orally active PKC beta inhibitor with a Ki value of 2 nM. Ruboxistaurin competitively inhibits PKC beta I (IC50: 4.7 nM) in an ATP-dependent manner. Ruboxistaurin is able to act o... |
|
T3689 |
Ruboxistaurin hydrochloride
|
Ruboxistaurin,LY333531 HCl,LY 333531 hydrochloride |
PKC
|
|
Ruboxistaurin hydrochloride (LY 333531 hydrochloride) is an Isozyme-selective inhibitor of protein kinase C (PKC); competitively and reversibly inhibits PKCβI and PKCβII (IC50 values are 4.7 and 5.9 nM respectively). Sel... |
|
T69990 |
Ruboxistaurin mesylate monohydrate
|
|
|
|
Ruboxistaurin mesylate monohydrate is a PKC beta inhibitor potentially for the treatment of diabetic nephropathy and diabetic macular edema. Ruboxistaurin attenuates diabetic nephropathy via modulation of TGF-β1/Smad and... |
|
T3689L |
Ruboxistaurin mesylate
|
LY-333531,LY333531,LY 333531,LY-333531 Mesylate |
|
|
Ruboxistaurin is a PKC beta inhibitor. Ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfunction in rats with streptozotocin-induced diabetes. Ruboxistaurin attenuates diabetic ne... |
|
T69989 |
(S)-Pomalidomide
|
|
|
|
(S)-Pomalidomide is an inhibitor of angiogenesis and growth of B-cell neoplasias, which induces complete regressions of Burkitt's lymphoma cell tumors. |
